📊 FBRX Key Takeaways
Is Forte Biosciences, Inc. (FBRX) a Good Investment?
Forte Biosciences is a pre-commercial biotech company with minimal revenue ($2.7M) and substantial operating losses ($22.4M annually), indicating an estimated 3-year cash runway at current burn rates despite adequate liquidity. While the strong cash position and manageable debt provide near-term stability, the company's path to profitability depends entirely on unvalidated pipeline success, making it a high-risk speculation without demonstrated clinical progress or commercialization milestones.
Forte Biosciences has a strong cash position and low near-term balance sheet stress, but its fundamentals remain dominated by heavy operating losses, deeply negative margins, and substantial cash burn relative to its very small revenue base. Revenue growth is not yet meaningful enough to demonstrate durable operating traction, so the company’s financial profile still depends more on preserving cash and achieving clinical or commercial progress than on proven business economics.
Forte Biosciences, Inc. Key Strengths (FBRX)
- Strong cash position of $58.2M provides 3+ years of R&D funding runway
- Healthy liquidity metrics with 2.75x current ratio and minimal long-term debt burden
- Manageable leverage at 0.52x debt-to-equity with positive stockholders' equity of $42.1M
- Revenue growing 106.6% year-over-year, though absolute base remains minimal
- Very strong liquidity, with $93.41M in cash and current and quick ratios of 7.34x
- Low balance sheet strain relative to equity, with debt-to-equity of 0.26x and liabilities well below assets
- Revenue grew 16.9% year over year, indicating some top-line improvement from a small base
FBRX Stock Risks: Forte Biosciences, Inc. Investment Risks
- Unsustainable burn rate of $18.8M annually with only $2.7M revenue creates acute dilution risk if capital raises required
- Operating margin of -826.5% indicates company is pre-profitability with no near-term path to positive operations
- Limited cash runway of approximately 3 years at current burn rate necessitates clinical success or capital raise
- Minimal insider trading activity (2 Form 4 filings) may signal lack of insider confidence in pipeline prospects
- Operating and net margins are extremely negative, showing the business is far from self-sustaining
- Free cash flow of -$34.53M implies a meaningful cash runway risk if burn is not reduced
- Revenue remains too small relative to the cost structure to validate growth quality or profitability improvement
Key Metrics to Watch
- Operating cash burn rate trend and cash runway calculations
- Quarterly revenue growth trajectory and timing to meaningful commercial scale
- Capital raising activities and dilution impact to existing shareholders
- Clinical trial progress and regulatory milestones for pipeline programs
- Quarterly operating cash burn relative to cash balance
- Revenue scale-up and operating loss reduction over the next several reporting periods
Forte Biosciences, Inc. (FBRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.75x current ratio provides a solid financial cushion.
FBRX Profit Margin, ROE & Profitability Analysis
FBRX vs Healthcare Sector: How Forte Biosciences, Inc. Compares
How Forte Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Forte Biosciences, Inc. Stock Overvalued? FBRX Valuation Analysis 2026
Based on fundamental analysis, Forte Biosciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Forte Biosciences, Inc. Balance Sheet: FBRX Debt, Cash & Liquidity
FBRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Forte Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-12.17 indicates the company is currently unprofitable.
FBRX Revenue Growth, EPS Growth & YoY Performance
FBRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2020 | $9.0K | -$10.3M | N/A |
| Q3 2019 | $9.0K | -$352.0K | N/A |
| Q2 2019 | $9.0K | -$16.0M | N/A |
| Q1 2019 | $9.0K | -$12.9M | N/A |
| Q3 2018 | $10.0K | -$352.0K | N/A |
| Q2 2018 | $9.0K | -$9.1M | N/A |
| Q1 2018 | N/A | -$9.1M | N/A |
| Q3 2017 | N/A | -$9.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Forte Biosciences, Inc. Dividends, Buybacks & Capital Allocation
FBRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Forte Biosciences, Inc. (CIK: 0001419041)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 2, 2026 | 4 | xslF345X06/form4-06022026_080622.xml | View → |
| Jun 2, 2026 | 4 | xslF345X06/form4-06022026_080621.xml | View → |
| Jun 2, 2026 | 4 | xslF345X06/form4-06022026_080621.xml | View → |
| Jun 2, 2026 | 4 | xslF345X06/form4-06022026_080615.xml | View → |
| Jun 2, 2026 | 4 | xslF345X06/form4-06022026_080600.xml | View → |
❓ Frequently Asked Questions about FBRX
What is the AI rating for FBRX?
Forte Biosciences, Inc. (FBRX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FBRX's key strengths?
Claude: Strong cash position of $58.2M provides 3+ years of R&D funding runway. Healthy liquidity metrics with 2.75x current ratio and minimal long-term debt burden. ChatGPT: Very strong liquidity, with $93.41M in cash and current and quick ratios of 7.34x. Low balance sheet strain relative to equity, with debt-to-equity of 0.26x and liabilities well below assets.
What are the risks of investing in FBRX?
Claude: Unsustainable burn rate of $18.8M annually with only $2.7M revenue creates acute dilution risk if capital raises required. Operating margin of -826.5% indicates company is pre-profitability with no near-term path to positive operations. ChatGPT: Operating and net margins are extremely negative, showing the business is far from self-sustaining. Free cash flow of -$34.53M implies a meaningful cash runway risk if burn is not reduced.
What is FBRX's revenue and growth?
Forte Biosciences, Inc. reported revenue of $2.7M.
Does FBRX pay dividends?
Forte Biosciences, Inc. does not currently pay dividends.
Where can I find FBRX SEC filings?
Official SEC filings for Forte Biosciences, Inc. (CIK: 0001419041) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FBRX's EPS?
Forte Biosciences, Inc. has a diluted EPS of $-1.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is FBRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Forte Biosciences, Inc. has a C grade with 81% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is FBRX stock overvalued or undervalued?
Valuation metrics for FBRX: ROE of -52.6% (sector avg: 15%), net margin of -815.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is FBRX's AI grade for 2026?
Our dual AI analysis gives Forte Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FBRX's free cash flow?
Forte Biosciences, Inc.'s operating cash flow is $-18.8M, with capital expenditures of $0.0. FCF margin is -692.7%.
How does FBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -815.3% (avg: 12%), ROE -52.6% (avg: 15%), current ratio 2.75 (avg: 2).